“To secure your chance at wealth you’ve only dreamed of, you must act BEFORE the NEXT shocking event, scheduled for Wednesday, September 23.
“That’s when the rest of the world will learn what you’ll know just seconds from now…
“We’re in the final warm-up laps now — the CEO’s news release I’ll tell you all about just confirmed that his work may be close to changing your life.
“It’s not an overstatement for me to say that my research will prove this moment could very well be the most profitable crossroads in human history.
“And in the next two minutes, I’ll introduce you to this CEO, his work — plus the work of five other companies currently on the verge of changing every life on the planet.”
That’s a good lead-in for the newest ad from Patrick Cox for his Breakthrough Technology Alert — we’re at what he’s calling a “Tipping Point” for this health technology, and that tipping point will bring huge profits for early investors.
I’ve written about this before, and it was for the same primary company being teased — and that stock has tripled since Cox first started teasing it last November.
Now, whether the tripling of the shares is due to real news and developments, or to hype and hope, is another question entirely — several of the big jumps in the share price, including today’s, seem to be attributable to nothing other than the ads for this newsletter. They are extraordinarily compelling ads, and many folks must either be subscribing, or visiting this site to find the answer, or sleuthing it out on their own.
But Cox has updated the ad, and where before it was a November announcement, almost a year ago, that was supposed to be your last chance to get in on the ground floor of a transformative new opportunity for investors … now it’s September 23.
And it’s the same guy talking — or at least, it was supposed to be (last-minute change of plans).
So what are we dealing with?
Perhaps a bit more hype first?
“Taken together, these six companies could alter the course of human history.
“This work could also make a select-few fast-movers like you very, very wealthy.
“Because the preparation is over. It’s time for a new century of wealth creation — it’s time for you to become ultra-wealthy….
“Just Six Tiny Companies Give You an Advantage Over Almost Every Investor on Earth.
“In fact, I’ve targeted the best six companies that are all (in one way or another) deeply involved in the research that could bring this advance to market.
“The brilliant CEO — a man I’ve actually been writing about to my readers for months — leads one of those companies.
“And as my research will show you today, this CEO’s press release which just hit his company website… well, it’s shocking to say the least.
“Because wrapped in this advance — deep inside all its potential to create great fortunes and make life better for each person on the planet… is one important realization.
“Here it is…
“One Epic News Release Confirms — This Advance Is Racing Toward Its Destiny of Changing the World…”
Sounds like something out of the new Dan Brown novel, doesn’t it? There’s more!
“Here’s the scoop on the recent news release from the CEO I’ll tell you all about today.
“On September 23, 2009 this CEO will speak in front of every major player in his industry. The press, analysts, and many other researchers will also be in attendance at this prestigious event.
“His remarks? I have word his comments will describe how his company’s technology can help solve a problem that just cost one famous company over $130 million in failed research.
“He’ll discuss new developments in his own company’s research too. PLUS — he’ll describe — in front of all these major players, a new business development for his firm that I predict could shake his industry, the markets, even the next day’s mainstream media news cycle to it’s very foundation.
“I can’t be more explicit than this — to see the biggest early gains and to ensure you have a chance to make the most profits in the long term, you absolutely must be on the inside BEFORE he takes the stage on Wednesday, September 23.”
OK, so … I won’t keep you waiting any longer. It appears almost certain to me that Cox is still teasing the same company, as I noted above, and that the company is still …
BioTime (BTIM). And yes, it’s up about 25-30% today — this same thing has happened to the stock several times as Cox ads have dragged it into the limelight.
I’d be extremely careful with these shares — we’re dealing with a teensy company that’s working on stem cell technology, so the stock (like most in the sector) is driven by hope and an unwritten future right now, which makes it easy for the shares to catapult and collapse, perhaps within the same week. That doesn’t mean it won’t be a great long term idea, of course, I have no idea … but it would not be shocking if much of today’s gain disappears if folks realize that the September 23rd speech is not, in fact, the catalyst for another sharp move upward.
Then again, I urged caution back in November, too, and while I was right that the shares would fall back immediately after the largely inconsequential but over-hyped speech by the CEO, Patrick Cox was certainly also right that the shares would climb in the longer term.
You can see my original article about that ad here if you’re curious.
So the company is BioTime, which also markets a blood plasma product but is primarily focused on technology and products for regenerative medicine and stem cell therapy. The CEO is Michael West, who has certainly been a pioneer in the industry, at several different companies — the speech he gave last November that was heavily teased by Patrick Cox was for the tenth anniversary of stem cell science … the speech he was supposed to be giving this time is at the World Stem Cell Summit in Baltimore. West got a better offer, so he will now be speaking on Tuesday in Beijing instead, at the China-USA Scientific Forum of Stem Cell and Regenerative Medicine — his speech at the Stem Cell Summit in Baltimore will now be presented instead by Dr. Walter Funk, also of BioTime.
And BioTime is essentially, it appears to me, a “picks and shovels” play on stem cells — this is a gross exaggeration, but they’re working to create and sell purified lines of stem cells and related regenerative medicine tools that can be used by other researchers, not to actually develop medicines or treatments themselves.
There are also, incidentally, warrants available on BioTime stock — listed as BTIMW, it looks like they give warrant holders the right to buy shares for $2 before October of 2010. They just raised another eight million dollars in share sales a few months ago, which included more of these warrants.
This is probably a good time to remind you that your friendly neighborhood Stock Gumshoe is not an expert on stem cells or any other area of biotech. He remembers beginning to dissect sharks and pigs in biology class, but passed out shortly thereafter and therefore had his learning cruelly cut short.
But I don’t think there’s nothing abundantly new here for longtime Gumshoe readers. As he did last November, Cox also teases some other companies. He doesn’t really give any clues to speak of, but we can start to look for them anyway, or at least make some guesses.
So what’s the next big thing in “regenerative medicine” (that seems to be the term most of them prefer now — perhaps because “stem cells” got politicized).
“The implications of what I’m describing are as huge as anything mankind has ever seen… and six tiny companies control all the most important technology…
“Today, I will tell you all about these six companies. I will show you everything I know — all my research — all my interviews.
“Which amazing company is led by a man who was awarded a Nobel Prize just a few years ago…
“Which company received a huge, $4.7 million grant to further refine their research and testing
“Plus all the details on yet another company that just signed a lucrative agreement with a big pharma firm that could be worth billions….
“Another company I’ll tell you all about in 6 World-Changing Companies To Deliver Your Ultra-Wealth has a revolutionary way to possibly treat (and maybe even someday cure) Alzheimer’s disease.
“Another company holds all the most important patents on pill delivery for what could develop into the best way to cure the body of its most terrible diseases…”
OK, so we do hear about BioTime again here — they’re the ones who got that $4.7 million grant, from the California Institute for Regenerative Medicine (remember that California was big in pushing for stem cell research back when the federal government was pushing the pause button? BioTime is a California company).
The one with a lucrative agreement with big pharma? I’ll throw out a wild guess that this is StemCells (STEM) — they bought Stem Cell Sciences, a UK firm that had a deal with Pfizer to supply stem cell lines and support research. Again, that’s just a guess — STEM will also be at the conference this week in Baltimore, as will most other companies in the business. They seem to be focused mostly on neurological applications of stem cells.
And the one with the Nobel prize winner? I don’t know of a stem cell company run by a Nobelist, though it’s possible I missed one, so I’ll guess that this is in another, somewhat related realm that Patrick Cox has also written about before — RNA interference (RNAi). That company is RXI Pharmaceuticals (RXII), founded by Craig Mello, who shared the Nobel Prize in 2006 for the discovery of RNAi.
Other stuff that was lightly teased in the ad included some potential to fight Alzheimer’s, which most scientists seem to think is a fool’s errand when it comes to stem cell treatments (what I’ve read indicates that other treatments for Alzheimer’s are much more likely to show good results, if only because this isn’t simply a matter of repairing damaged tissue), as well as treatments for diabetes and Parkinson’s, both of which are oft-cited (along with spinal injuries) as potential winners from stem cell advances.
So I can’t tell you which are Patrick Cox’s favorite six plays — I’m sure about BioTime, which continues to get most of his attention in these ads, but I’m definitely guessing on most of the others …
If you like BioTime you also might find it interesting to investigate the company from whom BioTime has licensed some of its technologies (Dr. West used to run this company, too, and owns some shares): Advanced Cell Technology (ACTC on the pink sheets). They gained fame for cloning embryonic stem cells and an endangered species, but they are now also focused on regenerative medicine at the moment.
And some further guesses: He might well be following International Stem Cell Corp (ISCO, over the counter), which is working on fighting rejection of donor cells, something he has written about before as being critical for near-term advances before the technology outgrows the need for donor stem cells … or Geron (GERN) a much higher-profile stem cell company that was also founded by Michael West (I don’t think he has any relationship with that company now).
So what do you think? Is it a good time to jump on BioTime after a huge run today? Any other stem cell and regenerative medicine companies capture your fancy? (There are hundreds of tiny ones, I’m afraid, and I have no idea which ones will really hit it big.)
Or have you ever subscribed to the Breakthrough Technology Alert (if so, please click here to review it for us — inquiring Gumshoes wanna know if it’s worth it).
And whether or not you believe in the long-term promise of this regenerative medicine investment thesis, which can be spun to support any of dozens of companies that are years away from being profitable, is this week the last chance to get in?
Who wants to place their bets as to whether either of these events, Michael West’s talk in Beijing tomorrow or the presentation of his colleague (and hundreds of others) at the World Stem Cell Summit this week, will be the “Tipping Point” moment that changes the future? Or, at least, launches these companies into the stratosphere of pluripotent profits?
Personal Capital is an advertiser with Stock Gumshoe, but Travis also uses it every day for his personal accounts and finds it invaluable. Here's what he said: "They offer a great (and genuinely FREE) 'second opinion' for your financial plan, but what I love most is their automated financial dashboard -- it will look at all your assets and debts, tally up your asset allocation, project where you'll be at retirement, and suggest ways to manage risk or improve returns. It's free, I think their free tools are great, and I think it's worth checking out -- you can do so here.